MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

OBJECTIVES: Primary * Estimate the maximum tolerated dose (MTD) and define the safety profile of multitargeted receptor tyrosine kinase inhibitor MP470 in humans. Secondary * Estimate the therapeutic response rate for patients receiving MP470. * Define the human pharmacokinetic (PK) and pharmacodynamic (PD) profiles of MP470 capsules * Evaluate PK-PD relationships. OUTLINE: This is a multicenter study. Patients receive oral multitargeted receptor tyrosine kinase inhibitor MP470 until the maximum tolerated dose is determined. Pharmacokinetic and pharmacodynamic analyses are carried out to determine changes in phosphorylation of extracellular signal-regulated kinase (ERK), Rad51 expression, number of circulating tumor cells (CTCs), and tumor glucose metabolism measured by 2-\[18F\]fluoro-2-deoxyglucose positron emission tomography (FDG-PET).